Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
02 May 2023 - 9:30PM
Business Wire
- The Blood-Brain-Barrier (BBB) prevents 98% of drugs from
entering the brain and is a major limiting factor in the
development of brain and central nervous system (CNS) drugs.
- Lantern’s AI algorithms for predicting BBB permeability have
89-92% accuracy, have been optimized to rapidly generate
predictions in around one minute, and are highly scalable to screen
thousands of compounds simultaneously.
- The Therapeutic Data Commons, an evaluator of
therapeutic-focused AI algorithms, has ranked Lantern’s four AI BBB
permeability prediction algorithms as the top four best performing
BBB prediction algorithms.
- The BBB permeability prediction AI algorithms are fully
integrated into Lantern’s AI platform RADR® and are being made
available to Lantern’s wholly-owned subsidiary, Starlight
Therapeutics, to further advance its brain and CNS cancer drug
programs.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("AI") and machine learning (“ML”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it has developed
highly-accurate and industry-leading AI algorithms to predict the
ability of a drug or compound to pass the blood-brain-barrier
(BBB), a highly selective border that can prevent drugs from
entering brain tissues. The BBB prevents an estimated 98% of drugs
from entering the brain, which presents a major hurdle for
developing drugs to treat brain and central nervous system (CNS)
cancers. Lantern’s AI BBB permeability prediction algorithms have a
prediction accuracy of 89-92% and represent a rapid and
cost-effective way to screen drugs or compounds to determine if
they cross the BBB, which can accelerate the development of drug
candidates for brain and CNS cancer patients.
“Lantern’s new BBB prediction module is a major development for
our AI RADR® platform and continues to demonstrate how Lantern is
applying AI to advance, de-risk, and significantly reduce costs in
oncology drug discovery,“ stated Panna Sharma, Lantern’s CEO and
President. “Biopharma companies can spend millions of dollars
annually on intensive wet-lab experiments to attempt to validate
whether a drug passes the BBB. Our AI/ML approach offers a rapid
and highly-accurate alternative for predicting a drug’s BBB
permeability, which will not only advance our drug development
pipeline, but will also facilitate opportunities for new high-value
business development collaborations with other biopharma companies
to develop brain and CNS drugs,” continued Sharma.
The highly accurate AI BBB permeability prediction algorithms
use a combination of proprietary automated feature selection
methods along with specialized hyper parameter optimization that
integrates algorithms using an ensemble approach to quickly provide
a compound’s BBB permeability range. This approach allows for high
throughput and ultra-fast BBB permeability analysis compared to
traditional discovery and evaluation methods.
Lantern’s AI BBB permeability prediction algorithms were
evaluated and scored in the BBB drug prediction challenge conducted
by Therapeutics Data Commons (TDC), a coordinated initiative to
evaluate AI capabilities across therapeutic modalities and stages
of discovery. This challenge evaluates and scores how AI/ML
algorithms perform in predicting the BBB permeability across 1,975
compounds whose BBB permeability is known. All four of Lantern’s
AI/ML BBB permeability prediction algorithms were the
top-performing algorithms evaluated by TDC and had high accuracy
prediction percentages ranging from 89-92% and high overall
performance scores ranging from 0.93-0.96 (out of 1). Lantern
expects to continue advancing its AI/ML BBB permeability prediction
algorithms to further increase their accuracy, performance, and
functionality.
Lantern’s AI BBB permeability prediction algorithms have been
fully integrated into RADR® as a BBB permeability prediction module
and continue to expand the diverse capabilities and functionality
of RADR®. Additionally, the RADR® BBB permeability prediction
module is being made available to the Company’s wholly-owned
subsidiary Starlight Therapeutics, to advance their pipeline of
brain and CNS cancer indications and will be leveraged to establish
additional RADR® focused biopharma collaborations for brain and CNS
drug discovery.
In addition to providing value for future biopharma
collaborations, the RADR® BBB permeability prediction module will,
more importantly, help to advance opportunities for the discovery
and development of new drug candidates for the hundreds of
thousands of brain and CNS cancer patients who have a large and
unmet need for new and effective cancer therapies.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® AI and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. By targeting
drugs to patients whose genomic profile identifies them as having
the highest probability of benefiting from the drug, Lantern's
approach represents the potential to deliver best-in-class
outcomes.
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Lantern Pharma Newsletter – The Spark: Sign-up here
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® AI platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2022,
filed with the Securities and Exchange Commission on March 20,
2023. You may access our Annual Report on Form 10-K for the year
ended December 31, 2022 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005542/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Apr 2024 to May 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From May 2023 to May 2024